BIM-23190 hydrochloride
PRODUCTS SPECIFICATIONS
DESCRIPTION
Overview
| MDL | - |
|---|---|
| Molecular Weight | 1238.91 |
| Molecular Formula | C57H80ClN13O12S2 |
| SMILES | - |
Summary
In Vitro
BIM-23190 tends to mildly stimulate PRL secretion [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
BIM-23190 (50 μg/mouse, twice a day) exhibits significant anti-tumor (C6 glioma) activity [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Male athymic nude (nu/nu) mice, 5-6 wk old (C6 glioma) [2] . |
| Dosage: | 50 μg/mouse. |
| Administration: | Injected twice a day for 19 days. |
| Result: | Significantly reduced the tumor growth rate. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Sealed storage, away from moisture
| Powder | -80°C | 2 years |
|---|---|---|
| -20°C | 1 year |
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 100 mg/mL ( 80.72 mM ; Need ultrasonic)
H 2 O : 100 mg/mL ( 80.72 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 0.8072 mL | 4.0358 mL | 8.0716 mL |
| 5 mM | 0.1614 mL | 0.8072 mL | 1.6143 mL |
| 10 mM | 0.0807 mL | 0.4036 mL | 0.8072 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (40.36 mM); Clear solution; Need ultrasonic
-
2.
-
3.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (2.02 mM); Clear solution
-
4.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (2.02 mM); Clear solution
References
- [1] I Shimon, et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest. 1997 Nov 1;100(9):
- [2] Federica Barbieri, et al. Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice. Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1078-88.
- [3] T J Gillespie, et al. Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution. J Pharmacol Exp Ther. 1998 Apr;285(1):95-104.